Sometimes All It Takes Is A Mention

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, June 22, 2022

In the biotech space, sometimes all it takes for a stock to move is a simple indication that things are going well during a specific trial or if there is any mention of the FDA. Just today, a small biotech company announced that the results from a small trial of just 18 rectal cancer patients in complete remission using an immunotherapy called dostarlimab are “impressive,” whilst acknowledging there’s more work to be done, according to the release. This simple mention sent shares of Propanc Biopharma Inc. (OTCQB:PPCB) soaring on Wednesday.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Traders were bullish on the news as shares climbed up to $0.0026/share (+23.81%) at the session high.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.